The coronavirus has had a negative impact on most but as luck would have it, some companies have benefited from the viral outbreak. Along with those catering to the stay at home climate, healthcare companies’ valuations have soared during the pandemic. You can add GenMark Diagnostics (GNMK) to the latter camp. The molecular diagnostics company has been no slouch in 2020, and shares are up by 288% so far.The stock was on the rise again yesterday after the company released impressive pre-earnings sales results.Specifically, GenMark expects Q2 revenue to come in at roughly $40 million, reflecting a 118% year-over-year increase and way ahead of the $31 million estimate. This is mainly off the back of the company’s ePlex SARS-CoV-2 test, which made up 48% ($16.9 million) of ePlex sales – compared to just 5% in Q1.The medical device specialist anticipates ePlex revenue to be up 195% year-over-year on overall sales of $35.2 million and the placement of 71 ePlex analyzers (up by 48%).In March, GenMark was granted Emergency Use Authorization (EUA) for its ePlex SARS-CoV-2 Test. Despite the strong demand, management has previously said that due to “manufacturing capacity constraints,” it does not expect revenue in 2020 to top $150 million. Nevertheless, Needham analyst Mike Matson expects GenMark to raise guidance when it reports earnings on August 3.The 5-star analyst said, “We believe that the COVID-19 pandemic continued to drive demand for GNMK's Respiratory Pathogen (RP) panel as a "rule-out" test and its separate COVID-19 test during 2Q20. GNMK launched its respiratory Pathogen Panel 2 (RP2) panel on 6/29/20, which added COVID-19 to the prior panel, so we expect the mix to shift back to its respiratory panel going forward… Given the strong ePlex placements and continued tailwind from COVID-19, we believe that GNMK can sustain strong growth throughout 2020.”Accordingly, Matson keep his Buy rating on GenMark intact, along with a $19 price target. What’s in it for investors? A modest upside of 2% from current levels. (To watch Matson’s track record, click here)Over the last 3 months, three other analysts have published a review of the diagnostics player’s prospects, all imploring investors to Buy. Yet, the average price target of $18 implies nearly 4% downside. (See GenMark stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * Apple Is Developing Its Own Graphics Cards- Report * Carnival (CCL) Is Still a Very Risky Cruise Line Stock * 3 Small-Cap Stocks Under $6 That Could See Over 70% Gains * Google Cloud Forges Multi-Year Deal With Renault

from Yahoo Finance https://ift.tt/2BR6azE

In a Yahoo Finance Premium webinar, Brian Shannon, CMT discusses why trading legends missed the bulk of the post-Covid stock market rally and explains how traders can avoid common pitfalls, such as impulsive trading, by having a trading plan and knowing their time frame.

from Yahoo Finance https://ift.tt/327Um6C

North Carolina-based asset management firm Massif Capital, LLC released its second-quarter investor letter this month – a copy of which is available for download here. The fund is currently being co-managed by Will Thomson and Chip Russell. In their recent letter to investors, Massif Capital announced that the core portfolio was up 18.3% in the […]

from Yahoo Finance https://ift.tt/38Lmi1w

Mesoblast has developed a cellular therapy that may significantly reduce deaths among the most severely sick COVID-19 patients. CEO Dr. Fred Grossman joins Yahoo Finance’s On the Move to discuss what this development could mean in the fight against the virus.

from Yahoo Finance https://ift.tt/2Ofx2f0

Amazon.com is launching a new fleet of bigger, boxier trucks like those favored by rival package carriers United Parcel Service Inc and FedEx Corp , as it fights to fix widespread pandemic-fueled delivery delays that sent customers into the arms of competitors like Walmart Inc . The world’s largest online retailer ordered more than 2,200 heavy-duty Utilimaster “walk-in” delivery trucks from Shyft Group , a Michigan-based specialty vehicle company, an Amazon spokeswoman told Reuters. The company declined to say how many of the vehicles have been sent to Amazon delivery contractors, or where they would be deployed.

from Yahoo Finance https://ift.tt/322T0Ki

2020 presidential candidate Joe Biden unveiled his economic plan, and called for an end to shareholder capitalism. Yahoo Finance’s Jessica Smith joins the On the Move panel to discuss.

from Yahoo Finance https://ift.tt/2ZVPY85

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is…

from Yahoo Finance https://ift.tt/2Of9RkZ

This market pro tells Yahoo Finance Joe Biden would not be good for investors. The explanation makes sense.

from Yahoo Finance https://ift.tt/38K5zeR

North Carolina-based asset management firm Massif Capital, LLC released its second-quarter investor letter this month – a copy of which is available for download here. The fund is currently being co-managed by Will Thomson and Chip Russell. In their recent letter to investors, Massif Capital announced that the core portfolio was up 18.3% in the […]

from Yahoo Finance https://ift.tt/38K0hQu

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story…

from Yahoo Finance https://ift.tt/38MdeJy